Clinical Trials on Recurrent Head and Neck Squamous Cell Carcinoma

Total 19559 results

Glenn J. Hanna
ImmunityBio, Inc.

Recruiting

PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Pharyngeal Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma of Unknown Primary | Resectable Head and Neck Squamous Cell Carcinoma

United States
Shyam S.D. Rao
National Cancer Institute (NCI)

Recruiting

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

Metastatic Head and Neck Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Refractory Head and Neck Squamous Cell Carcinoma

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC; Joseph Sanchez Foundation

Active, not recruiting

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center

Withdrawn

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Recruiting

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma

United States
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
University of Malaya
Merck Sharp & Dohme LLC; Cancer Research Malaysia; National Cancer Institute,... and other collaborators

Recruiting

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) (PIPER)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Malaysia
AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia, Canada, United Kingdom
M.D. Anderson Cancer Center

Recruiting

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
University College, London
Merck Sharp & Dohme LLC

Recruiting

Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (POPPY)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United Kingdom
Incyte Biosciences International Sàrl

Withdrawn

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Malignancies | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Korea, Republic of, Taiwan, Malaysia, United States
Emory University
Bristol-Myers Squibb; National Cancer Institute (NCI); The Cleveland Clinic; National... and other collaborators

Active, not recruiting

Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma

United States
Washington University School of Medicine
Eli Lilly and Company

Recruiting

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2)

Recurrent Head and Neck Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | HNSCC | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Locally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell Carcinoma

United States
Replimune Inc.
Bristol-Myers Squibb

Withdrawn

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Squamous Cell Carcinoma of Head and Neck | Recurrent Head and Neck Squamous Cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, United Kingdom, Czechia, France, Germany, Greece, Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Second Primary Squamous Cell Carcinoma of the Head and Neck

United States
Vanderbilt-Ingram Cancer Center
Boehringer Ingelheim; National Comprehensive Cancer Network

Withdrawn

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head or Neck | Metastatic Squamous Cell Carcinoma of the Head or Neck
Glenn J. Hanna
Secura Bio, Inc.

Active, not recruiting

Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

Metastatic Head and Neck Cancer | Advanced Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Advanced Head and Neck Cancer

United States
Hyunseok Kang, MD
NeoImmuneTech

Recruiting

NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Resectable Oropharyngeal Squamous Cell Carcinoma

United States
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
Trisha Wise-Draper
AstraZeneca

Active, not recruiting

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Metastatic Cancer | Recurrent Head and Neck Cancer

United States
NATCO Pharma Ltd.

Recruiting

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Carcinoma | Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

United States, India
Regeneron Pharmaceuticals
Sanofi

Completed

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Recurrent Squamous Cell Carcinoma of Head | Recurrent Squamous Cell Carcinoma of Neck | Metastatic Squamous Cell Carcinoma of Head | Metastatic Squamous Cell Carcinoma Neck

Korea, Republic of, United Kingdom
BioAtla, Inc.

Recruiting

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma of the Head and Neck

United States
PCI Biotech AS

Terminated

A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.

Recurrent Head and Neck Cancer | Carcinoma, Squamous Cell of Head and Neck

Germany, United Kingdom, France, Lithuania, Netherlands, Poland
PDS Biotechnology Corp.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (VERSATILE002)

HPV Positive Oropharyngeal Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Neoplasms, Head and Neck

United States, Puerto Rico, Ireland, United Kingdom
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

United States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
National Cancer Institute (NCI)

Completed

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma

United States
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

China
Nektar Therapeutics
Merck Sharp & Dohme LLC; SFJ Pharmaceuticals, Inc.

Terminated

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer

United States, Austria, Greece, Italy
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer | Recurrent Head and Neck Squamous Cell Cancer | Metastatic Head and Neck Squamous Cell Cancer

United States
Dan Zandberg

Recruiting

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

United States
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

China
Weill Medical College of Cornell University
Oncolys BioPharma Inc

Terminated

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma of the Hypopharynx | Metastatic Squamous Cell Carcinoma of the Larynx | Metastatic Squamous Cell Carcinoma of the Oral Cavity | Metastatic Squamous Cell Carcinoma of the Oropharynx | Recurrent Hypopharyngeal... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary | Recurrent Oral Cavity... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
Chase Heaton, MD
Incyte Corporation; OncoSec Medical Incorporated

Terminated

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma

United States
Amgen

Completed

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck

United States, Belgium, Czechia, Spain, Austria, France, Lithuania, Puerto Rico, Slovakia
Dan Zandberg
Merck Sharp & Dohme LLC

Active, not recruiting

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Recurrent Head and Neck Cancer | Carcinoma, Squamous Cell of Head and Neck

United States
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

China
Yonsei University

Completed

PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

Head Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell Metastatic

Korea, Republic of
Case Comprehensive Cancer Center

Not yet recruiting

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma

United States

Clinical Trials on Recurrent Head and Neck Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations